Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Current Liabilities (2016 - 2025)

Ani Pharmaceuticals' Total Current Liabilities history spans 16 years, with the latest figure at $278.1 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 43.02% year-over-year to $278.1 million; the TTM value through Dec 2025 reached $278.1 million, up 43.02%, while the annual FY2025 figure was $278.1 million, 43.02% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $278.1 million at Ani Pharmaceuticals, up from $270.6 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $278.1 million in Q4 2025 and bottomed at $79.5 million in Q1 2022.
  • The 5-year median for Total Current Liabilities is $130.1 million (2023), against an average of $143.9 million.
  • The largest annual shift saw Total Current Liabilities fell 3.91% in 2022 before it soared 69.19% in 2025.
  • A 5-year view of Total Current Liabilities shows it stood at $87.5 million in 2021, then increased by 13.6% to $99.4 million in 2022, then skyrocketed by 46.3% to $145.5 million in 2023, then soared by 33.67% to $194.5 million in 2024, then skyrocketed by 43.02% to $278.1 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Total Current Liabilities are $278.1 million (Q4 2025), $270.6 million (Q3 2025), and $236.8 million (Q2 2025).